USITC Announces Final Phase of Trade Investigations on Chromium Trioxide Imports

Estimated reading time: 3–5 minutes

The United States International Trade Commission (USITC) has announced the scheduling of the final phase of antidumping and countervailing duty investigations. This involves case numbers 701-TA-779 and 731-TA-1765-1766, focusing on chromium trioxide imports from India and Turkey.

The Commission aims to determine if these imports are harming the US industry. This investigation is under the Tariff Act of 1930.

Chromium trioxide is an inorganic compound with the chemical formula CrO3. It is often referred to as chromic acid in solution form. The investigations cover all forms of this chemical, whether solid or in solution form.

The Department of Commerce initially found that manufacturers from India might be subsidizing these products. It also noted that products from both India and Turkey are sold in the US at less-than-fair-value.

The investigations began after American Chrome & Chemicals, Inc., based in Pennsylvania, filed petitions in September 2025.

The USITC will hold a hearing in Washington, D.C. on August 6, 2026. The prehearing staff report will be released on July 24, 2026. Interested parties should attend the prehearing conference, if necessary, on August 4, 2026.

Parties must file written testimony and presentation slides by August 5, 2026. Prehearing briefs are due by July 31, 2026, and posthearing briefs by August 13, 2026.

All filings must be made electronically through the Commission’s system at edis.usitc.gov. No paper filings will be accepted during this time.

Individuals with questions should contact Laurel Schwartz at the Office of Investigations or visit usitc.gov for more information. The public can view records on the Commission’s electronic docket at edis.usitc.gov.

By order of the Commission, Lisa Barton, Secretary to the Commission, issued the notice on June 3, 2026.

Legal Disclaimer

This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.